A Jablonka1,2, P Solbach3,4, C Happle5,6, A Hampel7, R E Schmidt8,4, G M N Behrens8,4. 1. Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland. Jablonka.alexandra@mh-hannover.de. 2. Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, Hannover-Braunschweig, Deutschland. Jablonka.alexandra@mh-hannover.de. 3. Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland. 4. Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, Hannover-Braunschweig, Deutschland. 5. Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Medizinische Hochschule Hannover, Hannover, Deutschland. 6. Deutsches Zentrum für Lungenforschung (DZL), Standort Hannover, Hannover, Deutschland. 7. Klinik für Anästhesie, Notfallmedizin, Operative Intensivmedizin und Schmerztherapie, Klinikum Wolfsburg, Wolfsburg, Deutschland. 8. Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
Abstract
BACKGROUND: Germany is facing a huge humanitarian challenge with rapidly rising numbers of refugees entering the country. Data on hepatitis A seroprevalence and infection in refugees and asylum seekers in Europe during the current refugee exodus is scarce. OBJECTIVES: To assess hepatitis A (HAV) seroprevalence and immunity in refugees arriving in northern Germany in 2015. MATERIALS AND METHODS: A cross-sectional study of 235 refugees seeking shelter in reception centers in Northern Germany in August 2015 was performed, as acute Hepatitis A had been detected in one refugee in this camp. In order to analyze acute HAV infection and overall immunity, serological screening for HAV antibodies (combined IgG and IgM) was performed. The immunity threshold was defined as <20 IU/l. In all positive screening results, separate IgM testing was performed to detect acute infections. RESULTS: Males accounted for 84.3 % of HAV screened refugees and the mean age of refugees was 29.1 ± 11.2 years. Children and adolescents below the age of 18 years made up 8.8 % of the migrants. Overall HAV immunity within the cohort was 90 %, and a mild age-dependent increase in HAV immunity was observed, with 81.1 % immunity in children <18 years and a 100 % seropositivity in subjects >50 years. One 20-year-old female refugee had positive IgM results with high HAV antibodies, most likely due to subacute HAV infection. CONCLUSIONS: This comparably high rate of HAV protected refugees in our cohort supports the notion that the probability of large HAV outbreaks in current German refugee centers is low. However, depending on their current living situation, HAV vaccination should be considered for each refugee child, and healthcare providers and personnel working in refugee centers should be vaccinated against HAV.
BACKGROUND: Germany is facing a huge humanitarian challenge with rapidly rising numbers of refugees entering the country. Data on hepatitis A seroprevalence and infection in refugees and asylum seekers in Europe during the current refugee exodus is scarce. OBJECTIVES: To assess hepatitis A (HAV) seroprevalence and immunity in refugees arriving in northern Germany in 2015. MATERIALS AND METHODS: A cross-sectional study of 235 refugees seeking shelter in reception centers in Northern Germany in August 2015 was performed, as acute Hepatitis A had been detected in one refugee in this camp. In order to analyze acute HAV infection and overall immunity, serological screening for HAV antibodies (combined IgG and IgM) was performed. The immunity threshold was defined as <20 IU/l. In all positive screening results, separate IgM testing was performed to detect acute infections. RESULTS: Males accounted for 84.3 % of HAV screened refugees and the mean age of refugees was 29.1 ± 11.2 years. Children and adolescents below the age of 18 years made up 8.8 % of the migrants. Overall HAV immunity within the cohort was 90 %, and a mild age-dependent increase in HAV immunity was observed, with 81.1 % immunity in children <18 years and a 100 % seropositivity in subjects >50 years. One 20-year-old female refugee had positive IgM results with high HAV antibodies, most likely due to subacute HAV infection. CONCLUSIONS: This comparably high rate of HAV protected refugees in our cohort supports the notion that the probability of large HAV outbreaks in current German refugee centers is low. However, depending on their current living situation, HAV vaccination should be considered for each refugee child, and healthcare providers and personnel working in refugee centers should be vaccinated against HAV.
Authors: C Poethko-Müller; R Zimmermann; O Hamouda; M Faber; K Stark; R S Ross; M Thamm Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2013-05 Impact factor: 1.513
Authors: Annika Hampel; Philipp Solbach; Markus Cornberg; Reinhold E Schmidt; Georg M N Behrens; Alexandra Jablonka Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2016-05 Impact factor: 1.513
Authors: G Hendrickx; K Van Herck; A Vorsters; S Wiersma; C Shapiro; J K Andrus; A M Ropero; D Shouval; W Ward; P Van Damme Journal: J Viral Hepat Date: 2008-10 Impact factor: 3.728
Authors: Melissa G Collier; Yury E Khudyakov; David Selvage; Meg Adams-Cameron; Erin Epson; Alicia Cronquist; Rachel H Jervis; Katherine Lamba; Akiko C Kimura; Rick Sowadsky; Rashida Hassan; Sarah Y Park; Eric Garza; Aleisha J Elliott; David S Rotstein; Jennifer Beal; Thomas Kuntz; Susan E Lance; Rebecca Dreisch; Matthew E Wise; Noele P Nelson; Anil Suryaprasad; Jan Drobeniuc; Scott D Holmberg; Fujie Xu Journal: Lancet Infect Dis Date: 2014-09-03 Impact factor: 25.071
Authors: Martin Wetzke; Christine Happle; Annabelle Vakilzadeh; Diana Ernst; Georgios Sogkas; Reinhold E Schmidt; Georg M N Behrens; Christian Dopfer; Alexandra Jablonka Journal: Int J Environ Res Public Health Date: 2018-10-01 Impact factor: 3.390
Authors: Teresa Kloning; Thomas Nowotny; Martin Alberer; Michael Hoelscher; Axel Hoffmann; Guenter Froeschl Journal: BMC Public Health Date: 2018-08-07 Impact factor: 3.295